Search Results for: search.php

We would like to invite you to submit an abstract for the International Conference “Panacea Green Infrastructure? Multidimensional Contributions to Competitive…

DNA lesions occur in all living organisms. As accumulating DNA damage poses a risk for cell survival, cells harbour sophisticated mechanisms for repairing such lesions. The kinase ATR (“ATM and Rad3 related”) is a key player in triggering the cellular response to double strand DNA breaks called “DNA Damage Response” (“DDR”) thereby enabling DNA repair and thus promoting cell survical.

As cancer cells are often characterized by defects in various DNA repair processes and/or DNA damages, intact ATR-signalling (and subsequent DNA-repair processes) is particularly crucial for the viability of such cancer cells.

In fact, blocking DDR, preferably by inhibiting ATR has become an attractive therapeutic concept.

Correspondingly, at present, two ATR inhibitors (VX-970 and AZD5738; for ref. see “Relevant Publications”) have already entered clinical studies.

However, both with the developmental risk associated with these compounds, the need for compounds displaying an improved safety-/efficacy-profile and the large number of patients, there is a huge interest in advanced ATR inhibitors.

The present invention thus relates to advanced ATR antagonists which have proven to be effective in various in cellular assays (both on its own and in combination with cisplatin). Furthermore they show a promising ADME-profile as deducted from predictive ADME modelling and an improved solulibility in relation to the aforementioned compounds.

Selective Enhancement of Ligands by Exponential Enrichment (SELEX) has proven to be a powerful tool for idenfying functional oligonucleotides which bind to selected targets. Here, in an iterative process, a pool of single stranded oligonucleotides is contacted with a target structure (e.g. a protein), high-affinity oligonucleotides are then isolated, amplified and again put into contact with the target until, eventually, an ideal oligonucleotide has been obtained.
An International and a European patent application are pending. On behalf of University of Bonn, PROvendis offers licenses for commercial use as well a research collaboration with licensing option.

By cascading two DOEs are optical elements (lens, axicon, phase shifter, spiral phase plate) obtained, whose optical power can be adjusted continuously by just rotating one DOE with respect to the other.

Through photosynthesis, solar energy is converted into biological energy. It is often thought that photosynthesis becomes stronger as light becomes stronger,…

A novel mesh generation method enables a fast, fully automatic generation of high-quality meshes even for complex geometrical structures.